MP Group: Outlook on Global Medical Communications Outsourcing

Pleasure to share with you our Outlook on ‘Global Medical Communications Outsourcing’. Medical communications is becoming an integral part of drug development and commercialization strategy, owing to the pursuit of innovative and complex therapies, articulation of medical and economic benefits and adopting a patient-centric approach. As a result, the medical communications outsourcing market, from a current base of ~$2B in 2023, is expected to reach ~$8B by 2026, growing at a CAGR of 18%. The evolution of technology and omnichannel…

Continue Reading

MP Group: Outlook on Growth of the US biosimilars market – Key trends and opportunities

Pleasure to share our Outlook on Growth of the US biosimilars market – Key trends and opportunities. Historically, the US biosimilars market has posed several challenges restricting its penetration. Ambiguous regulatory guidelines contributing to high cost and timelines for development, patent dance causing uncertainties with launch timelines and barriers posed by the innovators limiting the market penetration – all of these led to the biosimilars market only dominated by the innovator companies. However, over the last 3-5 years, the landscape…

Continue Reading

Biospectrum: How Deep Tech is Powering India’s Biopharma Future

Advancements in cutting-edge innovative technologies and the increasing availability of data have enabled various domains of the biotech and pharma industries to leverage resourceful approaches in driving progress, maintaining competitive advantage and accomplishing the ultimate goal of improved patient outcomes. Deep tech ventures, also referred to as hard tech as opposed to regular digital platforms, primarily focus on the fundamental core issues of a business. For India to become an ‘innovation hub’, with concerted transformative efforts of leaders and experts…

Continue Reading

Drug Discovery and AI: overview of the main investments and partnerships of 2023

Artificial intelligence plays an increasing role in the discovery of new drugs. Which start-ups specializing in biotechnology have raised funds? For which therapeutic specialties or types of molecules? Which pharmaceutical laboratories support them? In partnership with Amandeep Singh, project manager at MP Advisors, mind Health has identified and analyzed the main announcements in the field in 2023. hile the search for new drugs is a long and expensive process, subject to high uncertainty, technology is playing an increasing role. Artificial intelligence (AI),…

Continue Reading

MP Group: Trends in the Bio-IT Services Industry

We are pleased to share with you our latest industry insights report titled Trends in the Bio-IT Services Industry. This report is based on insights derived from conversations with 50 CEOs of small to mid-sized companies providing life sciences-specific IT services across the R&D value chain. Digital transformation has become a top priority across the life sciences leadership, fuelling the growth of Bio-IT solutions companies at a remarkable pace. Over the last few years, the Bio-IT services companies are witnessing…

Continue Reading

MP Group: Outlook on Specialized Chemistry Outsourcing

It is our pleasure to share with you our Outlook on ‘Specialized Chemistry Outsourcing’ Complex modalities like ADCs, OligonucleoTIDES, PepTIDES (TIDES), etc. are becoming a key part of the biopharma pipeline, with applications across a wide range of indications. However, the infancy of ADC and the TIDES therapeutics pose several development and manufacturing challenges, from technology and process development to manufacturing and fill-finish. Therefore, biopharma is turning to outsourcing partners to offer strategic support to address these challenges. CDMOs, in…

Continue Reading

MP Group: Outlook on the CROs for the new-age Biopharma

It is our pleasure to share with you our outlook on the ‘CROs for the new-age Biopharma’. The drug development landscape is rapidly shifting towards complex targets and new drug modalities, with growth in cell & gene therapy and ADC pipeline now outpacing traditional small molecule drug candidates. As a result, the Biopharma cos are seeking CROs that can become an extension of their scientific think-tank, providing intellectual inputs and cutting edge research insights. It will be critical for CROs…

Continue Reading

MP Group: Outlook on the mRNA Bio-CDMOs – A key catalyst for the evolution of mRNA therapeutics

It is our pleasure to share with you our outlook on the ‘mRNA Bio-CDMOs – A key catalyst for the evolution of mRNA therapeutics.’ mRNA therapeutics played a pivotal role in the pandemic management thereby generating unparalleled interests (and investments) across the biopharma as well as investor groups. mRNA Covid-19 vaccines have paved the pathway for regulatory approvals. As a result, the clinical pipeline of mRNA therapeutics has expanded several fold across wide range of indications beyond infectious disease such…

Continue Reading

MP Group – A Global Outlook of HEOR (Health Economics and Outcomes Research) Services

We are glad to share our global outlook on Health Economics and Outcomes Research (HEOR) services. The field of Health Economics and Outcomes Research (HEOR) has undergone a significant transformation, shifting from a supportive role to a prominent position in the launch of drug products in the past decade. With the rising research and development costs, innovative therapeutic approaches and government initiative to curtail healthcare expenditures, we anticipate a persistent rise in the demand for HEOR services to demonstrate the…

Continue Reading

Pharmaphorum: Global upswing in medical writing, with a bout of M&A

The pharma industry has witnessed tremendous growth in the last decade with COVID-19 further fuelling the development of potential treatments, diagnostics, and vaccines at an unprecedented pace. There are now over 5000 companies involved in pharma R&D globally, approximately double that in 2012. The global pharma R&D spending increased from ~$130 billion in 2012 to ~$240 billion in 2022, leading to a doubling of the pipeline drug count. This swift pharma R&D growth has in turn accelerated the growth of…

Continue Reading
Close Menu